+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Thyroid Gland Disorders Treatment Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4622470
  • Report
  • May 2019
  • Region: Global
  • 115 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Abbvie Inc.
  • Amgen Inc.
  • Elexis Inc.
  • GlaxoSmithKline PLC
  • IBSA Pharma (IBSA Group)
  • Merck KGaA
  • MORE
Market Overview

The market for thyroid gland disorders treatment is primarily driven by the increasing burden of the patient population with iodine deficiency. One of the most common causes of iodine deficiency is very less good sources of iodine in the diet. As per World Health Organization (WHO), the recommended daily intake (RDI) is 150 mcg per day which is sufficient for more than 95% of all healthy adults, with pregnant and lactating women needing more. Iodine deficiency is increasingly common among the European countries and low and middle-income countries in the Asia Pacific and Africa. National Institute of Health has stated that the prevalence of Iodine Deficiency is higher in the mountainous regions of the United States and Mexico where more number of people are falling prey to the thyroid diseases.

Added to that high alcohol and tobacco consumption is also leading to thyroid disorders in the developing regions which are driving factors for the market studied.

Scope of the Report

The inefficiency of the thyroid gland to produce enough thyroid hormones leads to various kinds of thyroid gland related disorders.

Key Market Trends

Hyperthyroidism is Expected to Witness Rapid Growth

Hyperthyroidism is a condition in which the thyroid gland produces thyroxin in excess amount. As per the National Institute of Health, an estimated prevalence of the disease is around 1-1.3% and it increases up to 4-5% in the older women. Also, the disease more commonly occurs in smokers.

Since smoking is increasing among the general population across the globe, there is an increasing number of people that are falling prey to the disease. Also, the awareness about hyperthyroidism is increasing in developing countries such as India which is ultimately driving the growth of the market studied. Furthermore, the easy availability of the antithyroid medications for hyperthyroidism is fueling the market.

North America is Believed to Dominate the Market

In North America, it is estimated that about 35 million people suffer from at least one form of thyroid disease. Several companies have collaborated with ATA (America Thyroid Association), where ATA has supported several research grants with about USD 2.2 million. In addition, multinational companies have frequently involved in raising awareness in American society through campaigns. For instance, Merck launched “It’s not you. It’s your thyroid” campaign in 2017 and 2018. The annual awareness campaign is in collaboration with Thyroid Federation International (TFI), as it is observed by companies that the thyroid disorders are still poorly understood and often go underdiagnosed. The increased health infrastructure and high government involvement in the management of thyroid diseases make North America a major revenue contributor for the treatment of thyroid gland disorders treatment.

Competitive Landscape

The market for Thyroid Gland Disorder Treatment is moderately competitive and majorly consists of the global players. With the rising innovations in the therapeutics, it is believed that some small or mid-sized companies will be entering the market in the coming future.
Note: Product cover images may vary from those shown
2 of 4


  • Abbvie Inc.
  • Amgen Inc.
  • Elexis Inc.
  • GlaxoSmithKline PLC
  • IBSA Pharma (IBSA Group)
  • Merck KGaA
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Patient Population with Iodine Deficiency
4.2.2 Rising Government Initiatives for Thyroid Gland Screening and Treatment
4.3 Market Restraints
4.3.1 Unfavourable Healthcare Reforms in Some Regions
4.3.2 Alternative Herbal and Acupuncture Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Disorder
5.1.1 Hypothyroidism
5.1.2 Hyperthyroidism
5.1.3 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Others
5.3 By Drug Class
5.3.1 Thioamides
5.3.2 Ionic inhibitors
5.3.3 Hormone Release Inhibitors
5.3.4 Others
5.4 By Distribution Channel
5.4.1 Wholesale Distribution
5.4.2 Retail Stores
5.4.3 Online Pharmacy
5.5 Geography
5.5.1 North America US Canada Mexico
5.5.2 Europe Germany UK France Italy Spain Rest of Europe
5.5.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.5.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 Merck KGaA
6.1.5 Mylan NV
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Takeda Pharmaceutical Company Limited
6.1.9 Elexis Inc.
6.1.10 IBSA Pharma (IBSA Group)

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Abbvie Inc.
  • Amgen Inc.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc.
  • IBSA Pharma (IBSA Group)
Note: Product cover images may vary from those shown